Temat: "Heterocyclic Compounds, 3-Ring" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study.
Autorzy:: Shamu T; Newlands Clinic, Harare, Zimbabwe.; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.; Graduate School of Health Sciences, University of Bern, Bern, Switzerland.
Egger M; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.; Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa.; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Mudzviti T; Newlands Clinic, Harare, Zimbabwe.; Department of Pharmacy and Pharmaceutical Sciences, University of Zimbabwe, Harare, Zimbabwe.
Chimbetete C; Newlands Clinic, Harare, Zimbabwe.
Manasa J; Innovation Hub, University of Zimbabwe, Harare, Zimbabwe.
Anderegg N; Newlands Clinic, Harare, Zimbabwe.; Centre for Infectious Disease Epidemiology and Research, School of Public Health, University of Cape Town, Cape Town, South Africa.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Feb 23; Vol. 19 (2), pp. e0293162. Date of Electronic Publication: 2024 Feb 23 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Piperazines*
Pyridones*
Alkynes*
Oxazines*
Heterocyclic Compounds, 3-Ring*
Cyclopropanes*
Humans ; Female ; Male ; Atazanavir Sulfate/therapeutic use ; Longitudinal Studies ; Zimbabwe ; Bayes Theorem ; Benzoxazines/therapeutic use ; Viral Load

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
Autorzy:: Mendoza I; Pharmacy Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.; Alcalá University, Alcalá de Henares, Spain.
Lázaro A; Pharmacy Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Espinosa A; Internal Medicine Department, Research Unit, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Sánchez L; Internal Medicine Department, Research Unit, Hospital Universitario de Guadalajara, Guadalajara, Spain.
Horta AM; Pharmacy Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.; Alcalá University, Alcalá de Henares, Spain.
Torralba M; Alcalá University, Alcalá de Henares, Spain.; Internal Medicine Department, Research Unit, Hospital Universitario de Guadalajara, Guadalajara, Spain.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Sep 29; Vol. 18 (9), pp. e0291480. Date of Electronic Publication: 2023 Sep 29 (Print Publication: 2023).
Typ publikacji:: Observational Study; Journal Article
MeSH Terms:: HIV Infections*/drug therapy
Anti-HIV Agents*/adverse effects
Humans ; Adult ; Emtricitabine/therapeutic use ; Lamivudine/adverse effects ; Alanine/therapeutic use ; Heterocyclic Compounds, 3-Ring/adverse effects ; Pyridones/therapeutic use ; Adenine/therapeutic use ; Heterocyclic Compounds, 4 or More Rings/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir.
Autorzy:: Squillace N; Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
Ricci E; Fondazione ASIA Onlus, Buccinasco (MI), Italy.
Maggi P; Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy.
Taramasso L; Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy.
Menzaghi B; Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio (VA), Italy.
De Socio GV; Unit of Infectious Diseases, Santa Maria Hospital, Perugia, Italy.
Piconi S; Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy.
Maurizio Celesia B; Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy.
Orofino G; Division I of Infectious and Tropical Diseases, ASL Città di Torino, Torino, Italy.
Sarchi E; Infectious Diseases Unit, S.Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy.
Pellicanò GF; Infectious Diseases, G. Martino Hospital -University of Messina, Messina, Italy.
Simeone F; Infectious Diseases Unit, AORN Sant'Anna e San Sebastiano, Caserta, Italy.
Valsecchi L; 1st Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy.
Bandera A; Infectious Disease Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Cenderello G; Infectious Diseases Department, Sanremo Hospital, Sanremo, Italy.
Attala L; SOC 1 USLCENTRO FIRENZE, Unit of Infectious Diseases, Santa Maria Annunziata Hospital, Florence, Italy.
Angioni G; Infectious Diseases Unit, SS Trinità Hospital, Cagliari, Italy.
Falasca K; Clinic of Infectious Diseases, Department of Medicine and Science of Aging, G. D'Annunzio University, Chieti-Pescara, Chieti, Italy.
Cascio A; Unit of Infectious Diseases, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
Bargiacchi O; Unit of Infectious Diseases, Ospedale Maggiore della Carità, Novara, Italy.
Di Biagio A; Infectious Diseases, San Martino Hospital Genoa, University of Genoa, Genoa, Italy.
Bonfanti P; Infectious Diseases Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.; Department of Medicine, University of Milano-Bicocca, Milano (MI), Italy.; Pokaż więcej
Corporate Authors:: CISAI Study Group
Źródło:: PloS one [PLoS One] 2023 Aug 09; Vol. 18 (8), pp. e0289132. Date of Electronic Publication: 2023 Aug 09 (Print Publication: 2023).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: HIV Infections*/drug therapy
Anti-HIV Agents*/adverse effects
Male ; Humans ; Middle Aged ; Female ; Emtricitabine/adverse effects ; Alanine/therapeutic use ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Pyridones/therapeutic use ; Anti-Retroviral Agents/therapeutic use ; Lipoproteins, HDL

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria.
Autorzy:: Abudiore O; Clinton Health Access Initiative, Abuja, Nigeria.
Amamilo I; Clinton Health Access Initiative, Abuja, Nigeria.
Campbell J; Clinton Health Access Initiative, Abuja, Nigeria.
Eigege W; Clinton Health Access Initiative, Abuja, Nigeria.
Harwell J; Clinton Health Access Initiative, Abuja, Nigeria.
Conroy J; Clinton Health Access Initiative, Abuja, Nigeria.
Jiboye J; Clinton Health Access Initiative, Abuja, Nigeria.
Lufadeju F; Clinton Health Access Initiative, Abuja, Nigeria.
Amole C; Clinton Health Access Initiative, Abuja, Nigeria.
Wiwa O; Clinton Health Access Initiative, Abuja, Nigeria.
Anweh D; Department of Family Medicine, Federal Medical Centre Makurdi, Makurdi, Benue state, Nigeria.
Agbaji OO; Department of Medicine, Jos University Teaching Hospital, Katon Rikkos, Plateau state, Nigeria.
Akanmu AS; Department of Haematology and Blood transfusion, Lagos University Teaching Hospital, Lagos, Lagos State, Nigeria.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 May 17; Vol. 18 (5), pp. e0284767. Date of Electronic Publication: 2023 May 17 (Print Publication: 2023).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: HIV Infections*/drug therapy
Drug-Related Side Effects and Adverse Reactions*/drug therapy
Anti-HIV Agents*/adverse effects
Humans ; Female ; Middle Aged ; Male ; Prospective Studies ; Nigeria ; Oxazines/pharmacology ; Piperazines/pharmacology ; Heterocyclic Compounds, 3-Ring/adverse effects ; Pyridones/therapeutic use ; Viral Load

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
Autorzy:: Yamada E; Division of Oral and Maxillofacial Surgery, Faculty of Dentistry & Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Takagi R; Division of Oral and Maxillofacial Surgery, Faculty of Dentistry & Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Moro H; Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Sudo K; Hanah MediTech Co. Ltd., Tokyo, Japan.
Kato S; Hanah MediTech Co. Ltd., Tokyo, Japan.; Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Feb 18; Vol. 16 (2), pp. e0246994. Date of Electronic Publication: 2021 Feb 18 (Print Publication: 2021).
Typ publikacji:: Journal Article; Validation Study
MeSH Terms:: Drug Monitoring/*methods
HIV Infections/*drug therapy
HIV Integrase Inhibitors/*blood
Heterocyclic Compounds, 3-Ring/*blood
Oxazines/*blood
Piperazines/*blood
Pyridones/*blood
Tandem Mass Spectrometry/*methods
Chromatography, Liquid/methods ; Female ; HIV Integrase Inhibitors/therapeutic use ; HIV-1/drug effects ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Limit of Detection ; Male ; Oxazines/therapeutic use ; Piperazines/therapeutic use ; Pyridones/therapeutic use ; Saliva/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV.
Autorzy:: Correa A; Medical Sciences College, University of Pernambuco, Recife, Pernambuco, Brazil.
Monteiro P; Medical Sciences College, University of Pernambuco, Recife, Pernambuco, Brazil.
Calixto F; Teaching Hospital Oswaldo Cruz, University of Pernambuco, Recife, Pernambuco, Brazil.
Batista JDL; Medical Sciences College, Federal University of Fronteira Sul, Chapecó, Santa Catarina, Brazil.
de Alencar Ximenes RA; Medical Sciences College, University of Pernambuco, Recife, Pernambuco, Brazil.; Post-Graduation Program in Tropical Medicine, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Montarroyos UR; Institute of Biological Sciences, University of Pernambuco, Recife, Pernambuco, Brazil.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2020 Aug 31; Vol. 15 (8), pp. e0238052. Date of Electronic Publication: 2020 Aug 31 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Safety*
Anti-HIV Agents/*adverse effects
Anti-HIV Agents/*pharmacology
HIV Infections/*drug therapy
HIV Infections/*virology
Heterocyclic Compounds, 3-Ring/*adverse effects
Heterocyclic Compounds, 3-Ring/*pharmacology
Adolescent ; Adult ; Aged ; Anti-HIV Agents/therapeutic use ; Female ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Male ; Middle Aged ; Oxazines ; Piperazines ; Pyridones ; Retrospective Studies ; Virology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Antileishmanial activity of synthetic analogs of the naturally occurring quinolone alkaloid N-methyl-8-methoxyflindersin.
Autorzy:: Torres Suarez E; Grupo de Investigación en Inmunotoxicología, Departamento de Farmacia, Universidad Nacional de Colombia, Bogotá, Colombia.
Granados-Falla DS; Grupo de Investigación en Inmunotoxicología, Departamento de Farmacia, Universidad Nacional de Colombia, Bogotá, Colombia.; Vicerrectoría de Investigaciones, Universidad El Bosque, Bogotá, Colombia.
Robledo SM; PECET, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Murillo J; PECET, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Upegui Y; PECET, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Delgado G; Grupo de Investigación en Inmunotoxicología, Departamento de Farmacia, Universidad Nacional de Colombia, Bogotá, Colombia.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2020 Dec 28; Vol. 15 (12), pp. e0243392. Date of Electronic Publication: 2020 Dec 28 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antiprotozoal Agents/*pharmacology
Heterocyclic Compounds, 3-Ring/*pharmacology
Leishmania guyanensis/*drug effects
Leishmaniasis, Cutaneous/*drug therapy
Alkaloids/pharmacology ; Animals ; Antiprotozoal Agents/chemistry ; Cricetinae ; Disease Models, Animal ; Heterocyclic Compounds, 3-Ring/chemistry ; Humans ; Leishmania guyanensis/pathogenicity ; Leishmaniasis, Cutaneous/parasitology ; Leishmaniasis, Cutaneous/pathology ; Macrophages/drug effects ; Macrophages/parasitology ; Mice ; Nitric Oxide/genetics ; Plant Leaves/chemistry ; Quinolines/chemistry ; Quinolones/pharmacology ; Rutaceae/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
Autorzy:: Mellgren Å; Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Eriksson LE; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden.; School of Health Sciences, City, University of London, London, United Kingdom.; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Reinius M; Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden.
Marrone G; Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Svedhem V; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.; Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2020 Dec 23; Vol. 15 (12), pp. e0242710. Date of Electronic Publication: 2020 Dec 23 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Registries*
Alkynes/*adverse effects
Anti-HIV Agents/*adverse effects
Antiretroviral Therapy, Highly Active/*adverse effects
Benzoxazines/*adverse effects
Cyclopropanes/*adverse effects
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*adverse effects
Oxazines/*adverse effects
Piperazines/*adverse effects
Pyridones/*adverse effects
Quality of Life/*psychology
Adult ; Alkynes/administration & dosage ; Anti-HIV Agents/administration & dosage ; Arthralgia/chemically induced ; Arthralgia/diagnosis ; Arthralgia/physiopathology ; Benzoxazines/administration & dosage ; Cross-Sectional Studies ; Cyclopropanes/administration & dosage ; Erectile Dysfunction/chemically induced ; Erectile Dysfunction/diagnosis ; Erectile Dysfunction/physiopathology ; Female ; HIV/drug effects ; HIV Infections/physiopathology ; HIV Infections/psychology ; HIV Infections/virology ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Nausea/chemically induced ; Nausea/diagnosis ; Nausea/physiopathology ; Oxazines/administration & dosage ; Patient Reported Outcome Measures ; Piperazines/administration & dosage ; Pyridones/administration & dosage ; Sweden

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study.
Autorzy:: Nabitaka VM; Clinton Health Access Initiative, Kampala, Uganda.
Nawaggi P; Clinton Health Access Initiative, Kampala, Uganda.
Campbell J; Clinton Health Access Initiative, Kampala, Uganda.
Conroy J; Clinton Health Access Initiative, Kampala, Uganda.
Harwell J; Clinton Health Access Initiative, Kampala, Uganda.
Magambo K; Clinton Health Access Initiative, Kampala, Uganda.
Middlecote C; Clinton Health Access Initiative, Kampala, Uganda.
Caldwell B; Clinton Health Access Initiative, Kampala, Uganda.
Katureebe C; Ministry of Health, Kampala, Uganda.
Namuwenge N; Ministry of Health, Kampala, Uganda.
Atugonza R; Ministry of Health, Kampala, Uganda.
Musoke A; Clinton Health Access Initiative, Kampala, Uganda.
Musinguzi J; Ministry of Health, Kampala, Uganda.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2020 May 27; Vol. 15 (5), pp. e0232419. Date of Electronic Publication: 2020 May 27 (Print Publication: 2020).
Typ publikacji:: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: HIV Infections/*drug therapy
HIV Integrase Inhibitors/*therapeutic use
Heterocyclic Compounds, 3-Ring/*therapeutic use
Adult ; Antiretroviral Therapy, Highly Active/adverse effects ; Antiretroviral Therapy, Highly Active/methods ; Cohort Studies ; Female ; HIV Infections/virology ; HIV Integrase Inhibitors/adverse effects ; Heterocyclic Compounds, 3-Ring/adverse effects ; Humans ; Male ; Middle Aged ; Oxazines ; Patient Acceptance of Health Care ; Pilot Projects ; Piperazines ; Prospective Studies ; Pyridones ; Uganda ; Viral Load/drug effects ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding.
Autorzy:: Chitongo R; South African Medical Research Council Bioinformatics Unit, South African National Bioinformatics Institute, University of the Western Cape, Cape Town, South Africa.
Obasa AE; Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa.
Mikasi SG; Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa.
Jacobs GB; Division of Medical Virology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Cape Town, South Africa.
Cloete R; South African Medical Research Council Bioinformatics Unit, South African National Bioinformatics Institute, University of the Western Cape, Cape Town, South Africa.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2020 May 07; Vol. 15 (5), pp. e0223464. Date of Electronic Publication: 2020 May 07 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Mutation*
Drug Resistance, Viral/*genetics
HIV Infections/*metabolism
HIV Integrase/*genetics
HIV Integrase/*metabolism
HIV Integrase Inhibitors/*metabolism
HIV-1/*enzymology
Heterocyclic Compounds, 3-Ring/*metabolism
Amino Acid Sequence ; Catalytic Domain/genetics ; HIV Infections/drug therapy ; HIV Infections/virology ; HIV Integrase/chemistry ; HIV Integrase Inhibitors/therapeutic use ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Molecular Dynamics Simulation ; Oxazines ; Piperazines ; Protein Binding/genetics ; Protein Stability ; Pyridones ; Quinolones/metabolism ; Quinolones/therapeutic use ; Raltegravir Potassium/metabolism ; Raltegravir Potassium/therapeutic use ; South Africa ; Virus Replication/drug effects ; Virus Replication/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
Autorzy:: Frola CE; Research Department, Fundación Huésped, Buenos Aires, Argentina.; Division of Infectious Diseases, Juan A. Fernández Hospital, Buenos Aires, Argentina.
Aristegui I; Research Department, Fundación Huésped, Buenos Aires, Argentina.; Department of Research in Psychology, Universidad de Palermo, Buenos Aires, Argentina.
Figueroa MI; Research Department, Fundación Huésped, Buenos Aires, Argentina.
Radusky PD; Research Department, Fundación Huésped, Buenos Aires, Argentina.; Faculty of Psychology, Universidad de Buenos Aires, Buenos Aires, Argentina.
Cardozo N; Research Department, Fundación Huésped, Buenos Aires, Argentina.; Association of Transvestites, Transsexuals, and Transgenders of Argentina (A.T.T.T.A.), Buenos Aires, Argentina.
Zalazar V; Research Department, Fundación Huésped, Buenos Aires, Argentina.
Cesar C; Research Department, Fundación Huésped, Buenos Aires, Argentina.
Patterson P; Research Department, Fundación Huésped, Buenos Aires, Argentina.
Fink V; Research Department, Fundación Huésped, Buenos Aires, Argentina.
Gun A; Research Department, Fundación Huésped, Buenos Aires, Argentina.
Cahn P; Research Department, Fundación Huésped, Buenos Aires, Argentina.
Sued O; Research Department, Fundación Huésped, Buenos Aires, Argentina.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Jan 20; Vol. 18 (1), pp. e0279996. Date of Electronic Publication: 2023 Jan 20 (Print Publication: 2023).
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: HIV Infections*/drug therapy
Transgender Persons*
Adult ; Female ; Humans ; Anti-Retroviral Agents/therapeutic use ; Argentina/epidemiology ; Emtricitabine/therapeutic use ; Heterocyclic Compounds, 3-Ring/adverse effects ; Lamivudine/adverse effects ; Prospective Studies ; Pyridones/therapeutic use ; Tenofovir/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.
Autorzy:: Mandelbrot L; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Gynécologie-Obstétrique, Hôpitaux Universitaires Paris-Nord Val de Seine, Colombes, France.; Université Paris-Diderot, Université Sorbonne Paris-Cité, Paris, France.; Département Hospitalier Universitaire Risques et Grossesse, Paris, France.; IAME, UMR 1137, INSERM, Paris, France.
Ceccaldi PF; Université Paris-Diderot, Université Sorbonne Paris-Cité, Paris, France.; Département Hospitalier Universitaire Risques et Grossesse, Paris, France.; Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Service de Gynécologie-Obstétrique, Hôpitaux Universitaires Paris-Nord Val de Seine, Clichy, France.
Duro D; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Gynécologie-Obstétrique, Hôpitaux Universitaires Paris-Nord Val de Seine, Colombes, France.; Agence Nationale de Recherches sur le Sida et Hépatites Virales (Inserm-ANRS), Paris, France.
Lê M; IAME, UMR 1137, INSERM, Paris, France.; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Pharmaco-Toxicology Department, Hôpitaux Universitaires Paris-Nord Val de Seine, Paris, France.
Pencolé L; Assistance Publique-Hôpitaux de Paris, Hôpital Louis Mourier, Service de Gynécologie-Obstétrique, Hôpitaux Universitaires Paris-Nord Val de Seine, Colombes, France.; Université Paris-Diderot, Université Sorbonne Paris-Cité, Paris, France.; IAME, UMR 1137, INSERM, Paris, France.
Peytavin G; IAME, UMR 1137, INSERM, Paris, France.; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Pharmaco-Toxicology Department, Hôpitaux Universitaires Paris-Nord Val de Seine, Paris, France.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2019 Aug 13; Vol. 14 (8), pp. e0220323. Date of Electronic Publication: 2019 Aug 13 (Print Publication: 2019).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Maternal-Fetal Exchange*
HIV Integrase Inhibitors/*pharmacokinetics
Heterocyclic Compounds, 3-Ring/*pharmacokinetics
Placenta/*metabolism
Antipyrine/pharmacokinetics ; Female ; HIV Integrase Inhibitors/analysis ; Heterocyclic Compounds, 3-Ring/analysis ; Humans ; Models, Biological ; Oxazines ; Perfusion ; Piperazines ; Placenta/chemistry ; Pregnancy ; Pyridones

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Downregulation of SFRP2 facilitates cancer stemness and radioresistance of glioma cells via activating Wnt/β-catenin signaling.
Autorzy:: Wu Q; Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
Yin X; Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
Zhao W; Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
Xu W; Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.
Chen L; Department of Neurosurgery, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi Province, China.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Dec 01; Vol. 16 (12), pp. e0260864. Date of Electronic Publication: 2021 Dec 01 (Print Publication: 2021).
Typ publikacji:: Journal Article
MeSH Terms:: Down-Regulation*/drug effects
Radiation Tolerance*/drug effects
Brain Neoplasms/*pathology
Gene Expression Profiling/*methods
Glioma/*pathology
Membrane Proteins/*genetics
Neoplastic Stem Cells/*metabolism
Animals ; Brain Neoplasms/genetics ; Brain Neoplasms/radiotherapy ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Cell Proliferation/radiation effects ; Female ; Gene Expression Regulation, Neoplastic/drug effects ; Gene Expression Regulation, Neoplastic/radiation effects ; Glioma/genetics ; Glioma/radiotherapy ; Heterocyclic Compounds, 3-Ring/pharmacology ; Humans ; Male ; Mice ; Neoplasm Grading ; Neoplasm Transplantation ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/radiation effects ; Prognosis ; Sequence Analysis, RNA ; Wnt Signaling Pathway/drug effects ; Wnt Signaling Pathway/radiation effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort.
Autorzy:: Focà E; Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Calcagno A; Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy.
Calza S; Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.; BDbiomed lab, University of Brescia, Brescia, Italy.
Renzetti S; Unit of Biostatistics and Bioinformatics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.; BDbiomed lab, University of Brescia, Brescia, Italy.
Chiesa A; Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Siano M; 3rd Division of Infectious Diseases, University of Milano, L. Sacco Hospital, Milano, Italy.
De Socio G; Department of Infectious Diseases, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy.
Piconi S; 1st Division of Infectious Diseases Unit, University of Milano, L. Sacco Hospital, Milano, Italy.
Orofino G; Unit of Infectious Diseases, 'Divisione A', Amedeo di Savoia Hospital, ASLTO2, Torino, Italy.
Madeddu G; Unit of Infectious and Tropical Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy.
Cattelan AM; Unit of Infectious Diseases, Department of Internal Medicine, Azienda Ospedaliero-Universitaria di Padova, Padova, Italy.
Nozza S; Department of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy.
Ferrara M; Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy.
Milic J; Department of Mother, Child and Adult Medicine and Surgical Science, Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy.
Celesia BM; Division of Infectious Diseases, Department of Clinical and Molecular Biomedicine, University of Catania, ARNAS Garibaldi, Catania, Italy.
Castelli F; Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.
Guaraldi G; Department of Mother, Child and Adult Medicine and Surgical Science, Infectious Disease Clinic, University of Modena and Reggio Emilia, Modena, Italy.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Oct 13; Vol. 16 (10), pp. e0258533. Date of Electronic Publication: 2021 Oct 13 (Print Publication: 2021).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: HIV Infections/*drug therapy
HIV Integrase Inhibitors/*therapeutic use
Aged ; Amides/therapeutic use ; Anti-Retroviral Agents/therapeutic use ; Drug Therapy, Combination ; Female ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Longitudinal Studies ; Male ; Medication Adherence ; Oxazines/therapeutic use ; Piperazines/therapeutic use ; Polypharmacy ; Proportional Hazards Models ; Prospective Studies ; Pyridones/therapeutic use ; Quinolones/therapeutic use ; Raltegravir Potassium/therapeutic use ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.
Autorzy:: Capetti AF; 1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy.
Sterrantino G; Division of Infectious Diseases, 'Careggi', Hospital, Firenze, Italy.
Cossu MV; 1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy.
Orofino G; Division of Infectious Diseases, 'Amedeo di Savoia' Hospital, Torino, Italy.
Barbarini G; 2nd Division of Infectious Diseases, 'Policlinico San Matteo' Hospital, Pavia, Italy.
De Socio GV; Infectious Diseases Clinic, Azienda Ospedaliero-Universitaria di Perugia, Perugia, Italy.
Di Giambenedetto S; 2nd Division of Infectious Diseases, 'Policlinico Universitario Agostino Gemelli' Hospital, Roma, Italy.
Di Biagio A; Infectious Diseases Clinic, 'San Martino' Hospital, Genova, Italy.
Celesia BM; Infectious Diseases Unit, University of Catania, ARNAS (Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione) Garibaldi, Catania, Italy.
Argenteri B; 1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy.
Rizzardini G; 1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milano, Italy.; Whitwaterstrand University, Johannesburg, South Africa.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2016 Oct 14; Vol. 11 (10), pp. e0164753. Date of Electronic Publication: 2016 Oct 14 (Print Publication: 2016).
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: HIV Infections/*drug therapy
HIV Integrase Inhibitors/*therapeutic use
Heterocyclic Compounds, 3-Ring/*therapeutic use
Reverse Transcriptase Inhibitors/*therapeutic use
Rilpivirine/*therapeutic use
Adult ; Aged ; Antiretroviral Therapy, Highly Active ; Cohort Studies ; Creatinine/blood ; Drug Administration Schedule ; Drug Interactions ; Drug Resistance, Viral ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; HIV Infections/virology ; HIV Integrase Inhibitors/adverse effects ; HIV-1/genetics ; HIV-1/isolation & purification ; Headache/etiology ; Heterocyclic Compounds, 3-Ring/adverse effects ; Humans ; Male ; Middle Aged ; Oxazines ; Piperazines ; Pyridones ; RNA, Viral/blood ; Reverse Transcriptase Inhibitors/adverse effects ; Rilpivirine/adverse effects ; Sleep Initiation and Maintenance Disorders/etiology

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
Autorzy:: Rutherford GW; Global Health Sciences, University of California, San Francisco, San Francisco, California, United States of America.
Horvath H; Global Health Sciences, University of California, San Francisco, San Francisco, California, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2016 Oct 13; Vol. 11 (10), pp. e0162775. Date of Electronic Publication: 2016 Oct 13 (Print Publication: 2016).
Typ publikacji:: Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms:: Anti-HIV Agents/*therapeutic use
Antiretroviral Therapy, Highly Active/*methods
Benzoxazines/*therapeutic use
HIV Infections/*drug therapy
HIV-1/*drug effects
Heterocyclic Compounds, 3-Ring/*therapeutic use
Reverse Transcriptase Inhibitors/*therapeutic use
Alkynes ; Anti-HIV Agents/administration & dosage ; Benzoxazines/administration & dosage ; Cyclopropanes ; HIV Integrase Inhibitors/administration & dosage ; HIV Integrase Inhibitors/therapeutic use ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Humans ; Oxazines ; Piperazines ; Pyridones ; Reverse Transcriptase Inhibitors/administration & dosage

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Mode of Action of the Sesquiterpene Lactones Psilostachyin and Psilostachyin C on Trypanosoma cruzi.
Autorzy:: Sülsen VP; Cátedra de Farmacognosia, Instituto de Química y Metabolismo del Fármaco (Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Puente V; Centro de Investigaciones sobre Porfirinas y Porfirias (Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas), Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina.
Papademetrio D; Cátedra de Inmunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Batlle A; Centro de Investigaciones sobre Porfirinas y Porfirias (Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas), Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina.
Martino VS; Cátedra de Farmacognosia, Instituto de Química y Metabolismo del Fármaco (Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Frank FM; Cátedra de Inmunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.; Instituto de Microbiología y Parasitología Médica (Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas), Facultad de Medicina, UBA, Buenos Aires, Argentina.
Lombardo ME; Centro de Investigaciones sobre Porfirinas y Porfirias (Universidad de Buenos Aires - Consejo Nacional de Investigaciones Científicas y Técnicas), Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina.; Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2016 Mar 03; Vol. 11 (3), pp. e0150526. Date of Electronic Publication: 2016 Mar 03 (Print Publication: 2016).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Chagas Disease/*drug therapy
Heterocyclic Compounds, 3-Ring/*pharmacology
Lactones/*pharmacology
Pyrones/*pharmacology
Sesquiterpenes/*pharmacology
Trypanosoma cruzi/*drug effects
Ambrosia/chemistry ; Apoptosis/drug effects ; Chagas Disease/parasitology ; Hemin/metabolism ; Heterocyclic Compounds, 3-Ring/chemistry ; Heterocyclic Compounds, 3-Ring/metabolism ; Humans ; Lactones/chemistry ; Lactones/metabolism ; Plant Extracts/chemistry ; Plant Extracts/pharmacology ; Pyrones/chemistry ; Pyrones/metabolism ; Reactive Oxygen Species/metabolism ; Sesquiterpenes/chemistry ; Sesquiterpenes/metabolism ; Trypanosoma cruzi/pathogenicity

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.
Autorzy:: Pialoux G; Service des Maladies Infectieuses et Tropicales, AP-HP Hôpital Tenon, Paris, France.
Marcelin AG; Service de Virologie, AP-HP, Hôpital Pitié-Salpêtrière, INSERM-Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Paris, France.
Despiégel N; Optum, Paris, France.
Espinas C; Optum, Paris, France.
Cawston H; Mapi Group (previously Optum), Paris, France.
Finkielsztejn L; ViiV, Marly-le-Roi, France.
Laurisse A; ViiV, Marly-le-Roi, France.
Aubin C; GSK, Marly-le-Roi, France.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2015 Dec 29; Vol. 10 (12), pp. e0145885. Date of Electronic Publication: 2015 Dec 29 (Print Publication: 2015).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cost-Benefit Analysis*
HIV Infections/*drug therapy
HIV Integrase Inhibitors/*economics
HIV Integrase Inhibitors/*pharmacology
HIV-1/*physiology
Heterocyclic Compounds, 3-Ring/*economics
Heterocyclic Compounds, 3-Ring/*pharmacology
Adult ; Drug Resistance, Viral ; France ; HIV Integrase Inhibitors/therapeutic use ; HIV-1/drug effects ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Monte Carlo Method ; Oxazines ; Piperazines ; Pyridones ; Quality-Adjusted Life Years

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
Autorzy:: Auclair M; Sorbonne Université, Paris, France.; Inserm UMR_S938, Centre de Recherche Saint-Antoine, Paris, France.; ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.
Guénantin AC; Sorbonne Université, Paris, France.; Inserm UMR_S938, Centre de Recherche Saint-Antoine, Paris, France.; ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.
Fellahi S; Sorbonne Université, Paris, France.; Inserm UMR_S938, Centre de Recherche Saint-Antoine, Paris, France.; ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.; Department of Biochemistry, Tenon Hospital, APHP, Paris, France.
Garcia M; Sorbonne Université, Paris, France.; Inserm UMR_S938, Centre de Recherche Saint-Antoine, Paris, France.; ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.
Capeau J; Sorbonne Université, Paris, France.; Inserm UMR_S938, Centre de Recherche Saint-Antoine, Paris, France.; ICAN, Institute of Cardiometabolism and Nutrition, Paris, France.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2020 Jan 23; Vol. 15 (1), pp. e0226924. Date of Electronic Publication: 2020 Jan 23 (Print Publication: 2020).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents/*adverse effects
Coronary Vessels/*cytology
HIV Infections/*drug therapy
NF-kappa B/*metabolism
Sirtuin 1/*metabolism
Ubiquitin Thiolesterase/*metabolism
Anti-HIV Agents/therapeutic use ; Atazanavir Sulfate/adverse effects ; Atazanavir Sulfate/therapeutic use ; Cells, Cultured ; Comorbidity ; Coronary Vessels/drug effects ; Coronary Vessels/metabolism ; Endothelial Cells/cytology ; Endothelial Cells/drug effects ; Endothelial Cells/metabolism ; Female ; Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Insulin Resistance ; Male ; Maraviroc/adverse effects ; Maraviroc/therapeutic use ; Oxazines ; Piperazines ; Pyridones ; Ritonavir/adverse effects ; Ritonavir/therapeutic use ; Signal Transduction ; Ubiquitin Thiolesterase/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Comparison of an in-house 'home-brew' and commercial ViroSeq integrase genotyping assays on HIV-1 subtype C samples.
Autorzy:: Seatla KK; Botswana Harvard AIDS Institute Partnership Gaborone, Botswana.; Department of Medical Laboratory Sciences, School of Allied Health Professionals, University of Botswana, Gaborone, Botswana.
Choga WT; Division of Human Genetics, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Mogwele M; Botswana Harvard AIDS Institute Partnership Gaborone, Botswana.; Department of Medical Laboratory Sciences, School of Allied Health Professionals, University of Botswana, Gaborone, Botswana.
Diphoko T; Botswana Harvard AIDS Institute Partnership Gaborone, Botswana.; Department of Medical Laboratory Sciences, School of Allied Health Professionals, University of Botswana, Gaborone, Botswana.
Maruapula D; Botswana Harvard AIDS Institute Partnership Gaborone, Botswana.; Department of Medical Laboratory Sciences, School of Allied Health Professionals, University of Botswana, Gaborone, Botswana.
Mupfumi L; Botswana Harvard AIDS Institute Partnership Gaborone, Botswana.; Department of Medical Laboratory Sciences, School of Allied Health Professionals, University of Botswana, Gaborone, Botswana.
Musonda RM; Botswana Harvard AIDS Institute Partnership Gaborone, Botswana.; Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Rowley CF; Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Avalos A; Botswana Harvard AIDS Institute Partnership Gaborone, Botswana.; Careena Centre for Health, Gaborone, Botswana.; Ministry of Health and Wellness, Gaborone, Botswana.
Kasvosve I; Department of Medical Laboratory Sciences, School of Allied Health Professionals, University of Botswana, Gaborone, Botswana.
Moyo S; Botswana Harvard AIDS Institute Partnership Gaborone, Botswana.; Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Gaseitsiwe S; Botswana Harvard AIDS Institute Partnership Gaborone, Botswana.; Department of Immunology & Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2019 Nov 21; Vol. 14 (11), pp. e0224292. Date of Electronic Publication: 2019 Nov 21 (Print Publication: 2019).
Typ publikacji:: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Genotyping Techniques/*instrumentation
HIV Infections/*drug therapy
HIV Integrase/*genetics
HIV Integrase Inhibitors/*pharmacology
HIV-1/*genetics
Adult ; Botswana ; Drug Resistance, Viral/genetics ; Female ; HIV Infections/virology ; HIV Integrase/isolation & purification ; HIV Integrase Inhibitors/therapeutic use ; Heterocyclic Compounds, 3-Ring/pharmacology ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Humans ; Male ; Mutation ; Oxazines ; Piperazines ; Pyridones ; RNA, Viral/genetics ; RNA, Viral/isolation & purification

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Heterocyclic Compounds, 3-Ring"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Język